Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agents for prostate cancer (PyL™ and 1404); and imaging analysis technology (aBSI and PSMA AI). Progenics has three commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which are partnered with Bausch Health Companies Inc.
Company profile
Ticker
PGNX
Exchange
Website
CEO
David W. Mims
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Excelsior Life Sciences Ireland Limited • Molecular Insight Pharmaceuticals, Inc. • Molecular Insight Limited • Progenics Life Sciences Limited • Progenics Pharmaceuticals Nevada, Inc. • PSMA Development Company LLC • EXINI Diagnostics AB • MNTX Royalties Sub LLC ...
IRS number
133379479
PGNX stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
8 Jul 20
15-12G
Securities registration termination
2 Jul 20
25-NSE
Exchange delisting
22 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jun 20
Latest ownership filings
SC 13G/A
FARALLON CAPITAL MANAGEMENT LLC
8 Feb 22
SC 13G/A
FARALLON CAPITAL MANAGEMENT LLC
16 Feb 21
4
Asha Das
23 Jun 20
4
Benedict Osorio
23 Jun 20
4
Bryce Tenbarge
23 Jun 20
4
Vivien Wong
23 Jun 20
4
David W. Mims
23 Jun 20
4
Gerard Ber
23 Jun 20
4
Bradley L Campbell
23 Jun 20
4
Eric J Ende
23 Jun 20
Institutional ownership, Q3 2021
9.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 8.01 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Altiva Management | 8.01 mm | $0.00 |